Abstract:Significance The design of cell-penetrating long peptidomimetic scaffolds for interacting with large protein binding interfaces is challenging because they involve various necessary functional groups. Here we report the first series of helical sulfono-γ-AApeptides that disrupt protein–protein interactions. Specifically, we discovered that these helical mimetics can structurally and functionally mimic the B Cell Lymphoma 9 (BCL9) helix and disrupt cancer-related β-catenin/BCL9 protein–protein interaction in cells with excellent potency and specificity. Enzymatic stability studies demonstrate the remarkable stability of the helical sulfono-γ-AApeptides, augmenting their biological potential. This strategy could be adapted to target a myriad of other disease-related protein–protein interactions. The rational design of α-helix–mimicking peptidomimetics provides a streamlined approach to discover potent inhibitors for protein−protein interactions (PPIs). However, designing cell-penetrating long peptidomimetic scaffolds equipped with various functional groups necessary for interacting with large protein-binding interfaces remains challenging. This is particularly true for targeting β-catenin/BCL9 PPIs. Here we designed a series of unprecedented helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B Cell Lymphoma 9 (BCL9). Our studies show that sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9 and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL9 PPIs, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, our enzymatic stability studies demonstrate the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential. This work represents not only an example of helical sulfono-γ-AApeptides that mimic α-helix and disrupt protein–protein interactions, but also an excellent example of potent, selective, and cell-permeable unnatural foldameric peptidomimetics that disrupt the β-catenin/BCL9 PPI. The design of helical sulfono-γ-AApeptides may lead to a new strategy to modulate a myriad of protein–protein interactions.

Design and Application of an Α‐helix‐mimetic Scaffold Based on an Oligoamide‐Foldamer Strategy: Antagonism of the Bak BH3/Bcl‐xL Complex

Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.

Development of a Potent Bcl-xLAntagonist Based on Α-Helix Mimicry

Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-XL: Role of Non-Hot Spot Residues

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

Terphenyl-Based Bak Bh3 Alpha-Helical Proteomimetics As Low-Molecular-Weight Antagonists Of Bcl-X-L

Structure- and NMR-based Design of Novel Bcl-xL Antagonists.

Dynamical Binding of Hydrogen-Bond Surrogate Derived Bak Helices to Antiapoptotic Protein Bcl-X(L)

Binding of Anti-Apoptotic Bcl-2 with Different BH3 Peptides: A Molecular Dynamics Study

Synthesis and Helical Structure of Lactam Bridged BH3 Peptides Derived from Pro-Apoptotic Bcl-2 Family Proteins

Binding modes of Bcl-2 homology 3 (BH3) peptides with anti-apoptotic protein A1 and redesign of peptide inhibitors: a computational study

In silico design of potential Mcl-1 peptide-based inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

An Anthraquinone Scaffold for Putative, Two-Face Bim BH3 Α-Helix Mimic.

Structure Assembly of Bcl-xL Through Α5–α5 and Α6–α6 Interhelix Interactions in Lipid Membranes

Bcl-2 Protein Fusion with Bak Peptide: Homology Modeling and Analysis

Two‐Face, Two‐Turn Α‐helix Mimetics Based on a Cross‐Acridine Scaffold: Analogues of the Bim BH3 Domain

Inhibition of β-catenin/B cell lymphoma 9 protein−protein interaction using α-helix–mimicking sulfono-γ-AApeptide inhibitors

Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin

Interchain Doubly-Bridged Α-Helical Peptides for the Development of Protein Binders

Terephthalamide Derivatives As Mimetics of Helical Peptides: Disruption of the Bcl-x(L)/Bak Interaction.